Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | How BCMA targeting bispecific antibodies may impact the subsequent use of CAR-T therapy in myeloma

Amrita Krishnan, MD, City of Hope, Duarte, CA, briefly comments on how BCMA targeting bispecific antibodies may impact the subsequent use of BCMA targeting CAR-T therapy in patients with multiple myeloma. Dr Krishnan also highlights the promising response rates observed with the use of bispecifics, and the importance of monitoring risk of infection in heavily pre-treated patients. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.